GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Chase Sun Pharmaceutical Co Ltd (SZSE:300026) » Definitions » Enterprise Value

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Enterprise Value : ¥10,516 Mil (As of Jun. 06, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Tianjin Chase Sun Pharmaceutical Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tianjin Chase Sun Pharmaceutical Co's Enterprise Value is ¥10,516 Mil. Tianjin Chase Sun Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥529 Mil. Therefore, Tianjin Chase Sun Pharmaceutical Co's EV-to-EBIT ratio for today is 19.87.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Tianjin Chase Sun Pharmaceutical Co's Enterprise Value is ¥10,516 Mil. Tianjin Chase Sun Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥529 Mil. Therefore, Tianjin Chase Sun Pharmaceutical Co's EV-to-EBITDA ratio for today is 19.87.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Tianjin Chase Sun Pharmaceutical Co's Enterprise Value is ¥10,516 Mil. Tianjin Chase Sun Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥5,913 Mil. Therefore, Tianjin Chase Sun Pharmaceutical Co's EV-to-Revenue ratio for today is 1.78.


Tianjin Chase Sun Pharmaceutical Co Enterprise Value Historical Data

The historical data trend for Tianjin Chase Sun Pharmaceutical Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Chase Sun Pharmaceutical Co Enterprise Value Chart

Tianjin Chase Sun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,215.77 14,126.28 24,350.86 18,120.90 12,855.05

Tianjin Chase Sun Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,733.70 17,138.21 14,159.99 12,855.05 11,871.60

Competitive Comparison of Tianjin Chase Sun Pharmaceutical Co's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Chase Sun Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Chase Sun Pharmaceutical Co's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Chase Sun Pharmaceutical Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Tianjin Chase Sun Pharmaceutical Co's Enterprise Value falls into.



Tianjin Chase Sun Pharmaceutical Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Tianjin Chase Sun Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Tianjin Chase Sun Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Chase Sun Pharmaceutical Co  (SZSE:300026) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Tianjin Chase Sun Pharmaceutical Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10515.981/529.345
=19.87

Tianjin Chase Sun Pharmaceutical Co's current Enterprise Value is ¥10,516 Mil.
Tianjin Chase Sun Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥529 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Tianjin Chase Sun Pharmaceutical Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=10515.981/529.345
=19.87

Tianjin Chase Sun Pharmaceutical Co's current Enterprise Value is ¥10,516 Mil.
Tianjin Chase Sun Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥529 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Tianjin Chase Sun Pharmaceutical Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10515.981/5913.167
=1.78

Tianjin Chase Sun Pharmaceutical Co's current Enterprise Value is ¥10,516 Mil.
Tianjin Chase Sun Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5,913 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Chase Sun Pharmaceutical Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Tianjin Chase Sun Pharmaceutical Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Business Description

Traded in Other Exchanges
N/A
Address
No. 20, Quanfa Road, Tianjin Wuqing Development Area, Tianjin, CHN, 301700
Tianjin Chase Sun Pharmaceutical Co Ltd is a high-tech medicine and health industry group. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet-based therapy.
Executives
Yao Xiao Qing Director
Chen Rui Qiang Executives
Li Chun Xu Executives
Lan Wu Jun Directors, Directors, and Executives
Zheng Dan Directors, executives
Zhang Kun Executives
Gao Guo Wei Executives
Shang Xiao Mei Securities Affairs Representative
Sun Zhang Hai Director
Wu Guang Ning Supervisors
Wang Long Executives
Liu Qiang Supervisors
Ceng Guo Zhuang Director
Su Bing Jun Directors, executives
Nie Wei Supervisors

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Headlines

No Headlines